HRP20140978T1 - Trazodon i trazodon hidroklorid u proäśišä†enom obliku - Google Patents
Trazodon i trazodon hidroklorid u proäśišä†enom obliku Download PDFInfo
- Publication number
- HRP20140978T1 HRP20140978T1 HRP20140978AT HRP20140978T HRP20140978T1 HR P20140978 T1 HRP20140978 T1 HR P20140978T1 HR P20140978A T HRP20140978A T HR P20140978AT HR P20140978 T HRP20140978 T HR P20140978T HR P20140978 T1 HRP20140978 T1 HR P20140978T1
- Authority
- HR
- Croatia
- Prior art keywords
- trazodone
- aqueous phase
- phase
- organic
- process according
- Prior art date
Links
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 title claims 6
- 229960002301 trazodone hydrochloride Drugs 0.000 title claims 4
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 title claims 3
- 239000008346 aqueous phase Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000012074 organic phase Substances 0.000 claims 5
- 229960003991 trazodone Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 3
- 239000012071 phase Substances 0.000 claims 3
- 230000007704 transition Effects 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- -1 aliphatic amines Chemical class 0.000 claims 1
- 150000004982 aromatic amines Chemical class 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 150000007529 inorganic bases Chemical group 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 150000004714 phosphonium salts Chemical group 0.000 claims 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (6)
1. Postupak za proizvodnju trazodona i trazodon-hidroklorida, naznačen time, da obuhvaća slijedeće korake:
(a) pripremanje organske faze koja sadrži od 10 g do 50 g trazodona na 100 g organske faze, u najmanje jednom organskom otapalu koje je odabrano iz skupine koju čine alkoholi, eteri, ugljikovodici, ketoni i esteri;
(b) pripremanje vodene faze koja sadrži barem jednu baznu smjesu odabranu iz skupine koja sadrži najmanje jednu anorgansku bazu, najmanje jednu organsku bazu, ili njihove smjese;
(c) miješanje navedene vodene faze s navedenom organskom fazom, pri čemu je vodena faza dodana u količini od 30 g do 100 g na 100 g organske faze, i pri čemu je spomenuta bazna smjesa dodana u količini od 0,05 do 1 mola po molu trazodona;
(d) zagrijavanje na temperaturi od minimalno 40°C u trajanju od najmanje 30 minuta;
(e) dobivanje navedenog trazodona; i po izboru,
(f) izlaganje navedenog trazodona klorovodičnoj kiselini, kako bi se dobio trazodon-hidroklorid.
2. Postupak za proizvodnju sukladan zahtjevu 1, naznačen time, da je navedena organska baza odabrana iz skupine koju čine alifatski amini i aromatski amini.
3. Postupak za proizvodnju sukladan bilo kojem od prethodnih zahtjeva, naznačen time, da navedena vodena faza sadrži katalizator faznog prijelaza.
4. Postupak za proizvodnju sukladan zahtjevu 3, naznačen time, da je navedeni katalizator faznog prijelaza odabran iz skupine koju čine kvarterne amonijeve soli i kvarterne fosfonijeve soli.
5. Postupak za proizvodnju sukladan bilo kojem od zahtjeva 3 do 4, naznačen time, da navedena vodena faza sadrži katalizator faznog prijelaza, u količini od 0.05 g do 0.5 g na 100 g vodene faze.
6. Postupak za proizvodnju sukladan bilo kojem od prethodnih zahtjeva, naznačen time, da se zagrijavanje u navedenom koraku(d), provodi na temperaturi između 40°C i točke vrelišta smjese organske faze i vodene faze, u vremenskom periodu između 30 i 300 minuta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001603A ITMI20071603A1 (it) | 2007-08-03 | 2007-08-03 | Trazodone e trazodone cloridrato in forma purificata |
| US97653507P | 2007-10-01 | 2007-10-01 | |
| PCT/EP2008/059640 WO2009019133A1 (en) | 2007-08-03 | 2008-07-23 | Trazodone and trazodone hydrochloride in purified form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140978T1 true HRP20140978T1 (hr) | 2014-12-05 |
Family
ID=39064326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140978AT HRP20140978T1 (hr) | 2007-08-03 | 2014-10-14 | Trazodon i trazodon hidroklorid u proäśišä†enom obliku |
Country Status (23)
| Country | Link |
|---|---|
| US (19) | US8133893B2 (hr) |
| EP (1) | EP2178850B1 (hr) |
| JP (3) | JP5635401B2 (hr) |
| KR (2) | KR101505522B1 (hr) |
| CN (1) | CN101772490B (hr) |
| AR (1) | AR067773A1 (hr) |
| BR (1) | BRPI0814448B8 (hr) |
| CA (1) | CA2693095C (hr) |
| CY (1) | CY1115666T1 (hr) |
| DK (1) | DK2178850T3 (hr) |
| EA (1) | EA017019B1 (hr) |
| ES (1) | ES2517871T3 (hr) |
| GE (2) | GEP20135915B (hr) |
| HK (1) | HK1139405A1 (hr) |
| HR (1) | HRP20140978T1 (hr) |
| IL (2) | IL203294A (hr) |
| IT (1) | ITMI20071603A1 (hr) |
| MX (1) | MX2010001094A (hr) |
| PL (1) | PL2178850T3 (hr) |
| PT (1) | PT2178850E (hr) |
| SI (1) | SI2178850T1 (hr) |
| UA (1) | UA103597C2 (hr) |
| WO (1) | WO2009019133A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20071573A1 (it) | 2007-07-31 | 2009-02-01 | Acraf | Composizione farmaceutica liquida stabile a base di trazodone |
| ITMI20071603A1 (it) * | 2007-08-03 | 2009-02-04 | Acraf | Trazodone e trazodone cloridrato in forma purificata |
| WO2012072665A1 (en) | 2010-11-30 | 2012-06-07 | Pharmaneuroboost N.V. | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors |
| CN103853790B (zh) * | 2012-12-06 | 2016-04-06 | 腾讯科技（深圳）有限公司 | 移动终端浏览器的上传信息处理方法及装置 |
| WO2015110883A1 (en) * | 2014-01-21 | 2015-07-30 | Piramal Enterprises Limited | An improved process for the preparation of trazodone and hydrochloride salt thereof |
| CN105777745A (zh) * | 2016-03-29 | 2016-07-20 | 深圳市泛谷药业股份有限公司 | 一种盐酸曲唑酮的制备方法 |
| JP7301858B2 (ja) * | 2018-02-07 | 2023-07-03 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | トラゾドンの調製のための継続的なプロセス |
| RU2706700C1 (ru) | 2019-09-24 | 2019-11-20 | Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" | Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях |
| CN117517545A (zh) * | 2023-12-08 | 2024-02-06 | 重庆锐恩医药有限公司 | 一种盐酸曲唑酮有关物质检测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR8135E (hr) | ||||
| IT1066857B (it) * | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
| GB1117068A (en) * | 1965-12-15 | 1968-06-12 | Acraf | S-triazole-[4,3-a]-pyridine derivatives and processes for their preparation |
| FR8135M (hr) * | 1968-12-31 | 1970-08-10 | ||
| IT1047702B (it) * | 1975-07-24 | 1980-10-20 | Acraf | Nuova sintesi degli psicofarmaci denominati trazodone ed eteroperidone |
| US4465683A (en) * | 1979-09-14 | 1984-08-14 | Mead Johnson & Company | Anti-psychotic agents |
| US4254124A (en) * | 1979-09-24 | 1981-03-03 | Mead Johnson & Company | Antidepressant agent |
| US4252806A (en) * | 1979-09-24 | 1981-02-24 | Mead Johnson & Company | Triazoloquinolones |
| IT1211095B (it) * | 1981-08-17 | 1989-09-29 | Roma Aziende Chimiche Riunite | Impiego del trazodone nel trattamento delle ulcere gastroduodenali. |
| IT1233412B (it) * | 1987-12-02 | 1992-03-30 | Acraf | Uso del trazodone |
| IT1314283B1 (it) * | 1999-12-16 | 2002-12-06 | Acraf | Trazodone cloridrato ed un procedimento per prepararlo. |
| EA008705B1 (ru) * | 2003-04-08 | 2007-06-29 | Алгоркс Фармасьютикалз, Инк. | Получение и очистка синтетического капсаицина |
| CN101242856A (zh) * | 2005-09-09 | 2008-08-13 | 莱博法姆公司 | 持续药物释放的组合物 |
| ITMI20071573A1 (it) | 2007-07-31 | 2009-02-01 | Acraf | Composizione farmaceutica liquida stabile a base di trazodone |
| ITMI20071603A1 (it) * | 2007-08-03 | 2009-02-04 | Acraf | Trazodone e trazodone cloridrato in forma purificata |
-
2007
- 2007-08-03 IT IT001603A patent/ITMI20071603A1/it unknown
-
2008
- 2008-07-23 DK DK08775309.1T patent/DK2178850T3/en active
- 2008-07-23 PT PT08775309T patent/PT2178850E/pt unknown
- 2008-07-23 KR KR1020107004790A patent/KR101505522B1/ko active IP Right Grant
- 2008-07-23 BR BRPI0814448A patent/BRPI0814448B8/pt active IP Right Grant
- 2008-07-23 PL PL08775309T patent/PL2178850T3/pl unknown
- 2008-07-23 GE GEAP200812416A patent/GEP20135915B/en unknown
- 2008-07-23 EP EP08775309.1A patent/EP2178850B1/en active Active
- 2008-07-23 EA EA201070228A patent/EA017019B1/ru not_active IP Right Cessation
- 2008-07-23 GE GEAP200811709A patent/GEP20135926B/en unknown
- 2008-07-23 ES ES08775309.1T patent/ES2517871T3/es active Active
- 2008-07-23 WO PCT/EP2008/059640 patent/WO2009019133A1/en active Application Filing
- 2008-07-23 SI SI200831322T patent/SI2178850T1/sl unknown
- 2008-07-23 KR KR1020147027643A patent/KR20140133901A/ko not_active Application Discontinuation
- 2008-07-23 US US12/513,048 patent/US8133893B2/en active Active
- 2008-07-23 CA CA2693095A patent/CA2693095C/en active Active
- 2008-07-23 MX MX2010001094A patent/MX2010001094A/es active IP Right Grant
- 2008-07-23 CN CN2008801018236A patent/CN101772490B/zh active Active
- 2008-07-23 JP JP2010518621A patent/JP5635401B2/ja active Active
- 2008-07-23 UA UAA201000547A patent/UA103597C2/ru unknown
- 2008-08-01 AR ARP080103346 patent/AR067773A1/es not_active Application Discontinuation
-
2010
- 2010-01-13 IL IL203294A patent/IL203294A/en active IP Right Grant
- 2010-06-22 HK HK10106163.6A patent/HK1139405A1/xx unknown
-
2012
- 2012-02-10 US US13/370,735 patent/US8314236B2/en active Active
- 2012-09-14 US US13/617,907 patent/US20130012520A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/833,569 patent/US20130203771A1/en not_active Abandoned
- 2013-04-22 IL IL225873A patent/IL225873A/en active IP Right Grant
- 2013-11-06 US US14/073,130 patent/US20140057922A1/en not_active Abandoned
-
2014
- 2014-06-16 US US14/305,135 patent/US20140296250A1/en not_active Abandoned
- 2014-06-30 JP JP2014135096A patent/JP6513911B2/ja active Active
- 2014-10-14 HR HRP20140978AT patent/HRP20140978T1/hr unknown
- 2014-10-30 CY CY20141100896T patent/CY1115666T1/el unknown
- 2014-12-18 US US14/574,445 patent/US20150105402A1/en not_active Abandoned
-
2015
- 2015-06-29 US US14/753,435 patent/US20150297589A1/en not_active Abandoned
-
2016
- 2016-01-04 US US14/987,153 patent/US20160113926A1/en not_active Abandoned
- 2016-07-18 US US15/212,715 patent/US20160324853A1/en not_active Abandoned
-
2017
- 2017-01-25 US US15/414,837 patent/US20170128442A1/en not_active Abandoned
- 2017-03-08 JP JP2017044339A patent/JP2017141246A/ja active Pending
- 2017-08-09 US US15/672,725 patent/US20170333425A1/en not_active Abandoned
-
2018
- 2018-02-07 US US15/890,596 patent/US20180161323A1/en not_active Abandoned
- 2018-08-22 US US16/108,482 patent/US20180353503A1/en not_active Abandoned
-
2019
- 2019-04-09 US US16/378,773 patent/US20190231774A1/en not_active Abandoned
- 2019-10-15 US US16/601,762 patent/US20200038396A1/en not_active Abandoned
-
2020
- 2020-04-29 US US16/861,503 patent/US20200253965A1/en not_active Abandoned
- 2020-10-28 US US17/082,669 patent/US20210052577A1/en not_active Abandoned
-
2024
- 2024-01-12 US US18/411,219 patent/US20240139179A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140978T1 (hr) | Trazodon i trazodon hidroklorid u proäśišä†enom obliku | |
| ATE448786T1 (de) | Verfahren zur herstellung eines nikotinzuführenden produkts | |
| RU2014136174A (ru) | Способ получения цеолитного материала | |
| JP2009256615A5 (hr) | ||
| DE602007013179D1 (de) | Polymerisationsverfahren zur herstellung von monodisperser organisch/anorganischer verbundnanomikrokugel | |
| WO2013042973A3 (ko) | Ｉ-선 포토레지스트 조성물 및 이를 이용한 미세패턴 형성 방법 | |
| RU2014139431A (ru) | Неводная жидкая композиция для нанесения покрытия | |
| JP2010530018A5 (hr) | ||
| JP2006045523A5 (hr) | ||
| ATE512931T1 (de) | Verfahren zur herstellung von ammoniumheptamolybdat | |
| BR112016009727B1 (pt) | processo para a preparação de uma mistura de eteramina, e, composição | |
| ATE498617T1 (de) | Verfahren zur herstellung einer 3-o- alkylascorbinsäure | |
| BR112012014496B1 (pt) | processos para preparar uma mistura de eteramina, e para produzir um sistema de resina epóxi curado | |
| HRP20220271T1 (hr) | Čvrsti oralni pripravci sa sporim otpuštanjem | |
| EA201590537A1 (ru) | Способ получения тел для литейного производства из гранулированной смеси, содержащей модифицированную поликонденсированную смолу и поглотитель формальдегида | |
| DE602008005595D1 (de) | Anlage zur herstellung eines mehrteiligen sulphathaltigen bindemittels mit hoher mechanischer leistung aus gips oder derivaten davon, verfahren zur herstellung eines solchen bindemittels und sich daraus ergebendes bindemittel | |
| AR053366A1 (es) | Derivados de aril - sulfonamidas como inhibidores especificos de caspasa-10, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de la retinopatia diabetica. | |
| Su et al. | A novel approach for modeling diodes into FDTD method | |
| 백재호 et al. | Synthesis and charaterization of binder for binder jetting additive manufacturing | |
| Álvaro-Muñoz et al. | (1R, 2S)-ephedrine: a new self-assembling chiral template for the synthesis of aluminophosphaye frameworks | |
| BR112015004454A8 (pt) | método para produção de poliamidas por meio de policondensação de monômeros e/ou oligômeros formadores de poliamida | |
| 최유진 et al. | 2P-311 Benzene-1, 3, 5-Tricarboxamide Macrogelator for Stimuli-Responsive Light Shutter | |
| WO2012102498A3 (ko) | 임프린트 리소그래피용 광경화형 수지 조성물 | |
| TH168112A (th) | องค์ประกอบบิทูมินัสในรูปแบบของเม็ดแกรนูล และวิธีการสำหรับการเตรียมสิ่งเดียวกันนี้ | |
| TH97376B (th) | กระบวนการใหม่สำหรับการจัดเตรียมอนุพันธ์ควินิวคลิดิเนียม คาร์บาเมต |